Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chenming Zhong

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Frontiers in Cell and Developmental Biology|March 7, 2022
miR-1269a and miR-1269b: Emerging Carcinogenic Genes of the miR-1269 FamilyZijun Xie, Chenming Zhong, Shiwei Duan
Clinical and Translational Medicine|October 14, 2023
H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagyChenming Zhong, Zijun Xie, Shiwei Duan
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 15, 2021
The tumorigenic function of LINC00858 in cancerQiudan Zhang, Chenming Zhong, Shiwei Duan
Frontiers in Oncology|October 22, 2021
MiR-873-5p: A Potential Molecular Marker for Cancer Diagnosis and PrognosisYuhao Zou, Chenming Zhong, Zekai Hu, et al.
Journal of Cellular Physiology|October 14, 2021
LINC00662: A new oncogenic lncRNA with great potentialChenming Zhong, Qiudan Zhang, Mingfang Zhang, et al.
Cells|May 14, 2022
LINC00665: An Emerging Biomarker for Cancer Diagnostics and TherapeuticsChenming Zhong, Zijun Xie, Jinze Shen, et al.
Clinical and Translational Medicine|September 7, 2024
RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathyJinze Shen, Jianqiao Shentu, Chenming Zhong, et al.
Frontiers in Oncology|January 24, 2022
Aberrant Expression of miR-1301 in Human CancerChenming Zhong, Yiyao Dong, Qiudan Zhang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 24, 2022
LINC00963: A potential cancer diagnostic and therapeutic targetZijun Xie, Chenming Zhong, Jinze Shen, et al.
Frontiers in Immunology|July 5, 2022
MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and PrognosisChenming Zhong, Zijun Xie, Ling-Hui Zeng, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Frontiers in Cell and Developmental Biology|March 7, 2022
miR-1269a and miR-1269b: Emerging Carcinogenic Genes of the miR-1269 FamilyZijun Xie, Chenming Zhong, Shiwei Duan
Clinical and Translational Medicine|October 14, 2023
H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagyChenming Zhong, Zijun Xie, Shiwei Duan
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 15, 2021
The tumorigenic function of LINC00858 in cancerQiudan Zhang, Chenming Zhong, Shiwei Duan
Frontiers in Oncology|October 22, 2021
MiR-873-5p: A Potential Molecular Marker for Cancer Diagnosis and PrognosisYuhao Zou, Chenming Zhong, Zekai Hu, et al.
Journal of Cellular Physiology|October 14, 2021
LINC00662: A new oncogenic lncRNA with great potentialChenming Zhong, Qiudan Zhang, Mingfang Zhang, et al.
Cells|May 14, 2022
LINC00665: An Emerging Biomarker for Cancer Diagnostics and TherapeuticsChenming Zhong, Zijun Xie, Jinze Shen, et al.
Clinical and Translational Medicine|September 7, 2024
RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathyJinze Shen, Jianqiao Shentu, Chenming Zhong, et al.
Frontiers in Oncology|January 24, 2022
Aberrant Expression of miR-1301 in Human CancerChenming Zhong, Yiyao Dong, Qiudan Zhang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 24, 2022
LINC00963: A potential cancer diagnostic and therapeutic targetZijun Xie, Chenming Zhong, Jinze Shen, et al.
Frontiers in Immunology|July 5, 2022
MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and PrognosisChenming Zhong, Zijun Xie, Ling-Hui Zeng, et al.
Pageof 3